Trial of TRC105 and Sorafenib in Patients With HCC
Status:
Completed
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the phase 1b portion is to evaluate safety and tolerability and determine a
recommended phase 2 dose for TRC105 when added to standard dose sorafenib in patients with
hepatocellular carcinoma. Up to 18 patients will be treated.
The purpose of the phase 2 portion is to estimate the ORR of patients with hepatocellular
carcinoma by RECIST 1.1. Up to 21 patients will be treated in phase 2.